Efficacy of galcanezumab in migraine central sensitization

Efficacy of galcanezumab in migraine central sensitization

Abstract Galcanezumab, a monoclonal antibody targeting the calcitonin gene-related peptide pathway (CGRP mAb), acts peripherally due to its large size. However, recent studies have suggested that CGRP mAbs may also have a central mode of action. This study aimed to evaluate the central effects of ga...

Full description

Bibliographic Details
Main Authors: Daisuke Danno, Noboru Imai, Shigekazu Kitamura, Kumiko Ishizaki, Shoji Kikui, Takao Takeshima
Format: Article
Language:English
Published: Nature Portfolio 2024-09-01
Series:Scientific Reports
Subjects:
Migraine
Central sensitization
CGRP antibodies
Galcanezumab
Central effect
Interictal burden
Online Access:https://doi.org/10.1038/s41598-024-72282-6

Internet

https://doi.org/10.1038/s41598-024-72282-6

Similar Items